Skip to main
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc. reported a total revenue of $44 million, reflecting a 15% year-over-year growth in constant currency terms, which indicates a slight improvement from the previous quarter's growth rate of 14%. The company benefits from an increasing number of gene therapy programs across various stages, particularly in oncology and rare diseases, bolstering expectations for both commercial revenue and clinical trial activity. The positive momentum is further reinforced by the growing acceptance of cell and gene therapies in the market, driving a consistent upward trajectory in approved therapies and pipeline developments.

Bears say

CryoPort Inc. is experiencing a decline in funding for start-ups within its sector, which may adversely impact future growth and innovation, thereby creating a negative outlook for the company. Despite a 16% growth in Life Sciences Services revenue to $24 million, this growth rate has slowed compared to the previous quarter, and the adjusted EBITDA margin remains negative at (1.5%), which indicates persistent profitability challenges. Moreover, anticipated decreases in cell and gene therapy approvals, combined with a slowdown in demand for MVE freezers, contribute to the company's downward revisions in earnings per share for 2026.

CryoPort (CYRX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 9 analysts, CryoPort (CYRX) has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.